Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD광범위한 만성 GVHD가 있는 동종 줄기 세포 이식 후 토실리주맙 및 항바이러스제로 치료된 중증 COVID19의 임상 경과Case Reports Published on 2021-08-012022-09-11 Journal: Transplant infectious disease : an official journa [Category] SARS, 진단, 치료제, [키워드] allo-HSCT Allogeneic allogeneic hematopoietic stem cell transplantation Antiviral benefit Cell chronic graft-versus-host disease chronic GVHD clinical Combination coronavirus coronavirus disease coronavirus disease (COVID19) Coronavirus disease 2019 Course COVID-19 COVID19 develop discharged disease eyes full recovery Graft-versus-host disease GVHD Hematopoietic stem cell HSCT humanized monoclonal antibody IL6 Immunocompromised interferon knowledge liver Lopinavir Lopinavir/ritonavir lung male Mortality myelofibrosis Patient pulmonary infections recipient recipients respiratory respiratory manifestation respiratory manifestations ribavirin Ritonavir severe complication severe complications severe COVID-19 shown skin STEM stem cell stem cell transplant Stem cell transplantation Tocilizumab treated [DOI] 10.1111/tid.13576 PMC 바로가기 [Article Type] Case Reports
Wharton’s Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce SARS-CoV2-Induced Inflammatory Cytokines Under High Glucose and Uremic Toxin ConditionsOriginal Research Reports Published on 2021-08-012022-10-28 Journal: Stem cells and development [Category] COVID-19, MERS, SARS, [키워드] addition approach Calu-3 calu-3 cells chronic inflammation Comorbidity Concentration condition contribute contributed contributing to correlation COVID-19 COVID-19 patient Cytokine storm Diabetes Mellitus disease DM downregulation effort epithelial cell examined extracellular vesicle Extracellular vesicles Factor function Glucose human lung Jelly Meta-analysis Mortality MSCs NF-κB nuclear Organ failure outcome p65 Patient patients with COVID-19 Potential treatment RD reaction reduce renal Research SARS-CoV SARS-CoV-2 severe symptom severity of COVID-19 significant decrease STEM stem cell suggested systematic review the cytokine storm toxin toxins uremic viral infection was increased [DOI] 10.1089/scd.2021.0065 PMC 바로가기 [Article Type] Original Research Reports
Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells간엽줄기세포에 의한 염증성 사이토카인 폭풍의 조절Review Published on 2021-07-292022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] Affect Anti-inflammatory anti-inflammatory properties candidate cellular and molecular clinical trial complex coronavirus disease COVID-19 Cytokine storm syndrome death described develop disease Diseases Efficacy Factor immune regulation immune system Immunity immunosuppressive Inflammation Inflammatory factor Inflammatory response Interaction mechanism mesenchymal stem cell Mesenchymal stem cells molecular MSC MSCs Pathogenesis Pathways Sepsis shown STEM stem cell Stem cell therapy storm therapeutic Treatment vital role [DOI] 10.3389/fimmu.2021.726909 PMC 바로가기 [Article Type] Review
Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic DevelopmentsCovid-19에 대한 엑소 좀의 다양한 효과 : 전염에서 치료 적 발전으로의 진보의 관점Review Published on 2021-07-282022-08-31 Journal: Frontiers in Immunology [Category] MERS, SARS, 바이오마커, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus administration Anti-viral antiviral drug antiviral drugs approach causative agent cells combating Combination communication coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Cytokine storm Defense develop development Diagnosis disease Effect ENhance Exosome Exosomes global pandemic Host immunomodulatory infected cells Infection intercellular Intervention lung injuries mesenchymal stem cell Mesenchymal stem cells mitochondrial Mitochondrial function modulate MSCs new strain new strain of coronavirus Numerous pathway Pathways Patient Perspective produced Progress promote reduce respiratory respiratory tract SARS-CoV-2 SARS-COV-2 infection secreted secretion severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 similarity Spread stem cell structures suppress the cytokine storm therapeutic agents Therapeutic benefit therapeutic benefits Therapeutics Therapies Transmission Treatment Treatment strategies treatment strategy uninfected cells Vaccine development Vaccines virus virus-infected cell virus-infected cells viruses with COVID-19 [DOI] 10.3389/fimmu.2021.716407 PMC 바로가기 [Article Type] Review
Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future PerspectivesReview Published on 2021-07-222022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, [키워드] absence acute lung injury acute respiratory distress syndrome addition anti-apoptotic Anti-inflammatory anti-oxidative ARDS cell population clinical trial condition conditioned medium COVID-19 COVID-19 outbreak Culture current distress Donor effective Exosomes forms functional Future genetic manipulation growth heterogeneity histological incidence limitation Lung injury Mesenchymal stem cells morbidity and mortality MSC MSCs physiopathological mechanism Pneumonia proliferative regenerative respiratory Safe Secretome STEM stem cell Stress syndrome therapeutic therapeutic effect therapy Treatment [DOI] 10.3390/ijms22157850 PMC 바로가기 [Article Type] Review
Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trialWharton 's Jelly Mesenchymal 줄기 세포를 사용한 Covid-19 환자의 세포 요법 : 1 상 임상 시험Clinical Trial Published on 2021-07-162022-08-13 Journal: Stem Cell Research & Therapy [Category] SARS, 임상, [키워드] addition antibody antibody tests base biochemical tests both lungs caused CD4 CD8 Cell Cell therapy clinical trial COVID-19 antibody test COVID-19 antibody tests cytokine Cytokine storm Cytokine storms Cytokines Cytometry Efficacy enzyme tests FIVE flow cytometry headache IFN-γ IgG antibodies IgM and IgG IL-10 IL-6 immune system indicated Inflammation inflammation test inflammation tests Inflammatory cytokines inflammatory phase inhibit injecting intravenous injection Intravenous injection lung lung CT scan medication mesenchymal stem cell Mesenchymal stem cells modulate mortality rates MSCs myocardial enzyme tests New Patient patients patients with COVID-19 patients with COVID19 performed reduce mortality rate reduction in resolved respond Result Routine hematology tests routine tests SARS-CoV-2 SDF-1 serious complication severe COVID-19 stem cell subject supplementary material test results TGF-β therapy TNFα total score treated Treatment VEGF was done was performed were measured Wharton’s jelly Wharton’s jelly-derived mesenchymal stem cells Wharton’s jelly-derived MSC WJ-MSC zonal involvement [DOI] 10.1186/s13287-021-02483-7 PMC 바로가기 [Article Type] Clinical Trial
Combination of mesenchymal stem cells and nicorandil: an emerging therapeutic challenge against COVID-19 infection-induced multiple organ dysfunctionCommentary Published on 2021-07-152022-10-29 Journal: Stem Cell Research & Therapy [Category] COVID-19, SARS, [키워드] activity administration Apoptosis assumed attenuate Cell cell injury Compound COVID-19 cytokine expression death Effect Exosome homing Immune cell IMPROVE Inflammation Inflammatory response inhibiting lung Mesenchymal stem cells microenvironment modulate MSC multi-organ failure multiple organ dysfunction Nicorandil Nitrate pandemic paracrine pharmacological potassium channel Prevent protective effect reactive oxygen specy SARS-COV-2 infection stem cell survival therapeutic Treatment [DOI] 10.1186/s13287-021-02482-8 PMC 바로가기 [Article Type] Commentary
Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19Review Article Published on 2021-06-302022-10-04 Journal: NPJ Regenerative Medicine [Category] 임상, 치료제, [키워드] acute respiratory distress acute respiratory syndrome Adaptive immune response alleviate ARDS caused clinical clinical study clinical trial clinics coronavirus coronavirus disease COVID-19 COVID-19 patient cytokine production Cytokine storm death decrease develop effective Efficacy enrolled evaluate fraction hypoxia immunomodulatory IMPROVE infected patient Inflammatory cytokine lack majority Mesenchymal stem cells Mild-to-moderate mortality rate MSC MSCs multiple organ failure outcome pandemic Patient patients performed placebo-controlled reduce regenerative potential Safe SARS-CoV-2 severe COVID-19 patients severe COVID-19 symptoms severe symptoms Standard of care statistically stem cell Support survival Symptoms syndrome therapeutic therapeutic potential Treatment uncontrolled viral infection [DOI] 10.1038/s41536-021-00147-x PMC 바로가기 [Article Type] Review Article
SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cellsSARS-CoV-2 특이 T 세포 기억은 줄기 세포 유사 기억 T 세포의 성공적인 개발로 COVID-19 회복기 환자에서 10개월 동안 지속됩니다.Article Published on 2021-06-302022-09-12 Journal: Nature Communications [Category] MERS, SARS, 진단, 치료기술, [키워드] activation-induced markers Antimicrobial responses CD4 CD8 Cell cells contribute convalescent COVID-19 patients COVID-19 COVID-19 convalescent patient COVID-19 pandemic detectable development differentiation effective evaluate Ex vivo feasibility immune responses Immunity Immunological memory long-lasting Longevity measure memory memory T memory T cell memory T cells MHC-I observé pathogen peaking post-symptom onset proliferation proportion protective immune response Re-infection response responsible SARS-CoV-2 SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells severity of COVID-19 staining stem cell study period Support sustained T cell T cell memory T cell response T cell responses T cells vaccination viral clearance viral infection [DOI] 10.1038/s41467-021-24377-1 PMC 바로가기 [Article Type] Article
EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients입원한 SARS-CoV-2 감염 환자의 결과 예측을 위한 EASIXImmunology Published on 2021-06-232022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 바이오마커, [키워드] 95%CI Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Admission age allocation Allogeneic angiopoietin angiopoietin-2 (Ang-2) Biomarkers caused Cell Cohort Comorbidities Comorbidity Complication coronavirus disease Coronavirus disease 2019 Coronavirus-2 correlated Course COVID-19 COVID19 CXCL8 CXCL9 death disease dysfunction EASIX endothelial endothelial activation and stress index Endothelial cell Endpoint enrolled Gender hazard ratio health-care system help Hospital admission hospitalized patient hospitalized patients independent Intensive interferon-alpha interleukin Interleukin-18 life-threatening mechanical ventilation multivariable analysis Odds ratio outcome pandemic pathophysiology Patient patients treated patients with COVID-19 predict prediction prediction of outcome primary endpoint resources respiratory Result retained SARS-CoV-2 SARS-CoV2 (COVID- 19) Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus soluble thrombomodulin stem cell Stem cell transplantation Stress suppressor of tumorigenicity 2 (ST2) Surveillance survival the disease thrombomodulin were assessed [DOI] 10.3389/fimmu.2021.634416 PMC 바로가기 [Article Type] Immunology